Evidence map›Paper›PMID 25569206›Full record

SynthesisBMJ (Clinical research ed.)2015

Quantifying and monitoring overdiagnosis in cancer screening: a systematic review of methods.

Jamie L Carter, Russell J Coletti, Russell P Harris

Abstract readSystematic Review
In one paragraph

Synthesis in BMJ (Clinical research ed.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Overdiagnosis in atrial fibrillation screening with wearables.Scandinavian journal of primary health care · 2026
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Empowering patients? The role of self-referral in early cancer detection.The British journal of general practice : the journal of the Royal College of General Practitioners · 2026
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jamie L CarterDepartment of Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.
Russell J ColettiDivision of General Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Russell P HarrisSheps Center for Health Services Research, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA russell_harris@med.unc.edu.

Funding

Understanding Physicians' and Patients' Views of Harms and Clinical Preventive SP01HS021133 · AHRQ · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HARRIS, RUSSELL P · 2011 to 2013
$4.5M
AHRQ HHS P01 HS021133
6 · The paper itself

Abstract

objectiveTo determine the optimal method for quantifying and monitoring overdiagnosis in cancer screening over time.

designSystematic review of primary research studies of any design that quantified overdiagnosis from screening for nine types of cancer. We used explicit criteria to critically appraise individual studies and assess strength of the body of evidence for each study design (double blinded review), and assessed the potential for each study design to accurately quantify and monitor overdiagnosis over time. DATA SOURCES: PubMed and Embase up to 28 February 2014; hand searching of systematic reviews. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: English language studies of any design that quantified overdiagnosis for any of nine common cancers (prostate, breast, lung, colorectal, melanoma, bladder, renal, thyroid, and uterine); excluded case series, case reports, and reviews that only reported results of other studies.

results52 studies met the inclusion criteria. We grouped studies into four methodological categories: (1) follow-up of a well designed randomized controlled trial (n=3), which has low risk of bias but may not be generalizable and is not suitable for monitoring; (2) pathological or imaging studies (n=8), drawing conclusions about overdiagnosis by examining biological characteristics of cancers, a simple design limited by the uncertain assumption that the measured characteristics are highly correlated with disease progression; (3) modeling studies (n=21), which can be done in a shorter time frame but require complex mathematical equations simulating the natural course of screen detected cancer, the fundamental unknown question; and (4) ecological and cohort studies (n=20), which are suitable for monitoring over time but are limited by a lack of agreed standards, by variable data quality, by inadequate follow-up time, and by the potential for population level confounders. Some ecological and cohort studies, however, have addressed these potential weaknesses in reasonable ways.

conclusionsWell conducted ecological and cohort studies in multiple settings are the most appropriate approach for quantifying and monitoring overdiagnosis in cancer screening programs. To support this work, we need internationally agreed standards for ecological and cohort studies and a multinational team of unbiased researchers to perform ongoing analysis.

Indexed as

Early Detection of CancerCohort StudiesEvidence-Based MedicineHumansMass ScreeningNeoplasmsObservationOutcome Assessment, Health CarePractice Guidelines as TopicRandomized Controlled Trials as TopicTime Factors

Identifiers

PMID25569206
PMCPMC4332263

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.